Clinical trialNCT06562543RecruitingPhase 4Interventional

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

SponsorTakedaEnrollment78Colorectal Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants. Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Study Director
Takeda
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

45 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Puerto Rico

Fundacion de Investigacion de Diego (fdi Clinical Research)
San Juan, Puerto Rico
Completed

United States

Central Alabama Research
Birmingham, Alabama, United States
Khaleel Ashraf
Recruiting
University of Alabama at Birmingham
Birmingham, Alabama, United States
Garima Gupta
Recruiting
Ironwood Cancer and Research Centers
Chandler, Arizona, United States
Neel Dharia
Recruiting
University of Arizona
Tucson, Arizona, United States
Aaron Scott
Recruiting
University of California San Diego
La Jolla, California, United States
Gregory Botta
Recruiting
University of Southern California
Los Angeles, California, United States
Sandra Algaze
Recruiting
Pih Health Whittier Hospital
Whittier, California, United States
Andrew Pham
Recruiting
Christiana Care Health Services
Newark, Delaware, United States
Jamal Misleh
Recruiting
University of Florida
Gainesville, Florida, United States
Completed
Baptist Health - Miami Cancer Institute
Miami, Florida, United States
Withdrawn
University of Miami
Miami, Florida, United States
Withdrawn
Emory University
Atlanta, Georgia, United States
Olatunji Alese
Recruiting
Hope and Healing Cancer Services
Hinsdale, Illinois, United States
Srilata Gundala
Recruiting
Indiana University
Indianapolis, Indiana, United States
Anita Turk
Recruiting
Our Lady of the Lake Physician Group - Lsu Health Baton Rouge Oncology
Baton Rouge, Louisiana, United States
Marshall Stagg
Recruiting
Willis Knighton Cancer Center
Shreveport, Louisiana, United States
Joyce Feagin
Recruiting
Mercy Medical Center
Baltimore, Maryland, United States
Panayotis Ledakis
Recruiting
Boston Medical Center
Boston, Massachusetts, United States
Withdrawn
Hattiesburg Clinic
Hattiesburg, Mississippi, United States
John Hrom
Recruiting
Midwest Oncology Associates - Kansas City
Kansas City, Missouri, United States
Jaswinder Singh
Recruiting
Saint Luke'S Cancer Institute
Kansas City, Missouri, United States
Withdrawn
Ssm Health St. Louis Depaul Hospital
St Louis, Missouri, United States
Brian Smith
Recruiting
Washington University School of Medicine
St Louis, Missouri, United States
Nikolaos Andreatos
Recruiting
Capital Health Medical Center - Hopewell
Pennington, New Jersey, United States
Hongyan Liang
Recruiting
Columbia University
New York, New York, United States
Withdrawn
Albert Einstein College of Medicine
The Bronx, New York, United States
Withdrawn
James J Peters Veterans Administration Medical Center - Navref
The Bronx, New York, United States
Withdrawn
Zangmeister Cancer Center
Columbus, Ohio, United States
Sameh Mikhail
Recruiting
Hightower Clinical Research
Oklahoma City, Oklahoma, United States
Completed
Fox Chase Cancer Center | Philadelphia, Pa
Philadelphia, Pennsylvania, United States
Withdrawn
Jefferson Health
Philadelphia, Pennsylvania, United States
Atrayee Basu-Mallick
Recruiting
Medical University of South Carolina
Charleston, South Carolina, United States
Withdrawn
University of Tennessee -- Memphis
Memphis, Tennessee, United States
Saurin Chokshi
Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Brooke Looney
Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Nilesh Verma
Recruiting
Renovatio Clinical
El Paso, Texas, United States
Mary Crow
Recruiting
Baylor College of Medicine
Houston, Texas, United States
Karen Riggins
Recruiting
Oncology Consultants - Memorial City Location
Houston, Texas, United States
Julio Peguero
Recruiting
Brcr Global
Katy, Texas, United States
Withdrawn

5 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Fruquintinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Jan 2025
Primary completion: 4 Oct 2027
Completion: 4 Oct 2027
Last update posted: 7 Jul 2026
Registered enrollment: 78
Registry id: NCT06562543

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.